



First Patients Enrolled at Allergy Partners in the US

Melbourne, Australia – 25 September 2023: Adherium Limited (ASX: ADR), a leading digital health company specialising in remote patient monitoring and data solutions for respiratory patients, has commenced the implementation of its collaboration with US-based Allergy Partners with the first patients enrolled onto the Hailie® platform at the largest allergy and asthma physician group in the US.

The initial patient group onboarded receives services at the Asheville, NC-based practice, near the Allergy Partners Corporate Headquarters. This implementation milestone marks an important step forward in transforming asthma care for more than 300,000 patients under the management of Allergy Partners.

The collaborative asthma management program will be rolled out at practices in two additional states with training continuing this month and more markets to follow this calendar year. The implementation plan is focused on leveraging Adherium's state-of-the-art Hailie sensor technology and software platform to monitor inhaler use and technique to increase patient engagement with their asthma care.

Allergy Partners and Adherium are committed to delivering the highest level of care and ensuring patient satisfaction. In addition to improving patient quality of life, Hailie enables doctors to bill for long-term, remote patient management under established US reimbursement codes. Adherium gets paid for sensor sales and by receiving monthly, per patient fees for generating and transmitting respiratory data.

Enquiries:

Rick Legleiter

CEO

Adherium Limited

investors@adherium.com

Rudi Michelson

Monsoon Communications

rudim@monsoon.com.au

Approved for release by the Board of Directors

-ENDS-

About Adherium

Adherium Limited (ASX: ADR) is a digital health company providing solutions for improving patient treatment with remote monitoring and data solutions. Its Hailie® system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. Hailie improves patient health through better adherence and self-management while enabling doctors to be paid for remote work and saving costs across health systems by avoiding hospital admissions. Adherium's clinically proven sensors, app and powerful data platform provide remote, real-time, personalised information to patients and clinicians. Adherium is increasing sales in US, UK and other markets by pursuing partnerships with major hospital systems, medical groups and insurers. For more information, visit <https://www.adherium.com/>